The FDA accepted vepdegestrant’s new drug application for ER+/HER2–, ESR1-mutated advanced breast cancer with a June 5, 2026, ...

Arvinas, in collaboration with Pfizer, has announced new drug application (NDA) acceptance for vepdegestrant from the US Food ...

The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling ...

Study participants were randomly assigned to receive either oral vepdegestrant (n=313) or intramuscular fulvestrant (n=311). The primary endpoint was progression free survival (PFS) among all patients ...

Pfizer (PFE) recently announced that the U.S. Food and Drug Administration accepted the New Drug Application for ...

US FDA accepts Arvinas’ NDA for vepdegestrant to treat ESR1m, ER+/HER2- advanced breast cancer: New Haven, Connecticut Monday, August 11, 2025, 17:00 Hrs [IST] Arvinas, Inc., a ...

Shares of Arvinas Inc. (ARVN) fell 4% on Thursday as Wall Street sounded contradicting opinions on the future of its ...

Newcomers will not only be plugging into UPS while its forward-looking yield stands at 7.4%, but while the stock's priced ...

Instead of acting via classical receptor antagonism, vepdegestrant enlists the cell's native protein degradation machinery to degrade the estrogen receptor.

5 high-yield stock picks to add to your dividend portfolio It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth.

If you can look just a little further down the road though, some new blockbuster drugs are in the works -- drugs like vepdegestrant, for the treatment of ER+/HER2- metastatic breast cancer.